Lead Product(s): PB2452
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: SFJ Pharmaceuticals
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2020
The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.